The purpose of the study is to determine whether stopping the use of these medications in patients whose gout is in remission, as monitored by ultrasound scans, is as effective as continuing the treatment in preventing future gout flares over a period of two years. Participants in the study will either continue their current medication or stop taking it, and their health will be monitored through regular check-ups and ultrasound scans to observe any changes in their condition.

The study will last for several years, with participants being observed at different intervals to track the occurrence of gout flares and other health indicators. The goal is to understand the long-term effects of maintaining or withdrawing urate-lowering therapy in patients with gout and to assess the impact on their overall health and quality of life. This research aims to provide valuable insights into the management of gout and help improve treatment strategies for patients in the future.

The purpose of the study is to compare two different strategies for using Febuxostat in treating gout. One group of participants will start taking Febuxostat immediately after a gout attack, while the other group will begin taking it six weeks after the attack. The study will observe the number of days participants experience gout symptoms over a period of about six weeks. Participants will be asked to keep a daily logbook to record whether they have experienced gout symptoms each day.

Throughout the study, participants will also be monitored for pain levels, overall function, and any side effects they may experience from the treatment. The study will last for several months, with assessments taking place at different intervals to gather comprehensive data on the effectiveness and tolerance of the treatment. This research aims to provide valuable insights into the best timing for starting Febuxostat treatment in managing gout effectively.

The purpose of the study is to evaluate the effectiveness of these treatments in managing the most severe pain experienced during an acute gout attack. Participants in the study will receive either Prednisolone, Colchicine, or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers know which treatment each participant is receiving, to ensure unbiased results.

Throughout the study, participants will take the medication orally for a period of up to five days. Researchers will monitor the participants’ pain levels, joint swelling, and overall physical function. The study aims to determine which treatment provides the best relief from pain and improves joint function during an acute gout attack. Participants’ feedback on the success of the treatment and any additional pain relief methods used will also be collected to provide a comprehensive understanding of the treatment’s effectiveness.

Participants in the study will be randomly assigned to receive either dapansutrile or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will last for a short period, during which participants will take the medication and report on their pain levels at various intervals.

In addition to dapansutrile, the study will also involve the use of paracetamol, a common pain reliever, to help manage symptoms. Participants will be monitored closely to assess any changes in their condition and to ensure their safety throughout the study. The goal is to determine if dapansutrile can effectively reduce the pain associated with an acute gout flare, providing a potential new treatment option for those affected by this painful condition.

The purpose of the study is to compare two strategies: continuing urate-lowering therapy versus stopping it in patients whose gout is in remission. Remission means that the patient has not experienced any gout flares, visible uric acid deposits called tophi, or significant pain due to gout for at least 12 months. The study will last for 24 months, during which participants will be monitored to see if they continue to meet the criteria for remission.

Participants will be randomly assigned to either continue their current urate-lowering medication or to stop taking it. The study will assess how many participants in each group remain in remission during the last six months of the study. This will help determine the best strategy for managing gout in remission. Additionally, the study will evaluate the cost-effectiveness of these strategies, which means it will look at the balance between the benefits of the treatment and its costs.

The purpose of this study is to determine how well Tigulixostat works in reducing uric acid levels in patients with gout and hyperuricemia. Participants will be randomly assigned to receive either Tigulixostat, Allopurinol, or a placebo. The study will last for several months, during which participants will have regular check-ups to monitor their uric acid levels and overall health. The goal is to see if Tigulixostat can help achieve and maintain lower uric acid levels over time, specifically aiming for levels below 6 mg/dL at certain points during the study.

Throughout the study, participants will be observed for any potential side effects or adverse reactions to the medications. The study will also track the occurrence of gout flares, which are sudden and severe attacks of pain and swelling in the joints, and the resolution of any existing tophi, which are lumps formed by uric acid crystals. The safety of the treatments will be closely monitored through various health assessments, including physical exams and laboratory tests. The study is expected to provide valuable information on the potential benefits and risks of Tigulixostat for patients with gout and hyperuricemia.